Amgen, Inc.

How big is Amgen, Inc.?

As of Jun 18, Amgen, Inc. has a market capitalization of $155.96 billion, with net sales of $33.93 billion and net profit of $5.93 billion over the latest four quarters.

As of Jun 18, Amgen, Inc. has a market capitalization of 155,961.65 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest 4 quarters is 33,929.00 million, while the sum of Net Profit for the same period is 5,933.00 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 5,877.00 million and Total Assets at 91,839.00 million.

What does Amgen, Inc. do?

Amgen, Inc. is a large-cap biotechnology company that develops and manufactures human therapeutics, with recent net sales of $8.1 billion and a net profit of $1.7 billion. Key financial metrics include a P/E ratio of 22.00 and a dividend yield of 3.18%.

Overview:<BR>Amgen, Inc. is a biotechnology company that discovers, develops, manufactures, and delivers various human therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8,093 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,730 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 155,961.65 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00 <BR>Dividend Yield: 3.18% <BR>Debt Equity: 7.83 <BR>Return on Equity: 116.13% <BR>Price to Book: 25.13<BR><BR>Contact Details:<BR>Address: 1 Amgen Center Dr, THOUSAND OAKS CA: 91320-1730 <BR>Tel: 1 805 4471000 <BR>Fax: 1 805 4471010 <BR>Website: http://www.amgen.com

Who are in the management team of Amgen, Inc.?

As of March 2022, Amgen, Inc.'s management team includes Chairman and CEO Robert Bradway, Lead Independent Director Robert Eckert, and Independent Directors Wanda Austin, Brian Druker, Gregory Garland, and Fred Hassan.

As of March 2022, the management team of Amgen, Inc. includes Mr. Robert Bradway, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. Robert Eckert holds the position of Lead Independent Director. The board also comprises several Independent Directors: Dr. Wanda Austin, Dr. Brian Druker, Mr. Gregory Garland, and Mr. Fred Hassan.

Should I buy, sell or hold Amgen, Inc.?

Is Amgen, Inc. overvalued or undervalued?

As of October 17, 2025, Amgen, Inc. is considered undervalued with attractive metrics, including a P/E ratio of 22 and a PEG ratio of 0.27, especially compared to Gilead Sciences, and despite a 7.01% decline in stock price over the past year, it offers a strong ROE of 116.13% and a dividend yield of 3.18%.

As of 17 October 2025, the valuation grade for Amgen, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 22, a PEG ratio of 0.27, and an EV to EBITDA ratio of 14.13, suggesting that the stock is priced lower relative to its growth potential compared to peers. <BR><BR>In comparison to its peer Gilead Sciences, Inc., which has a P/E of 15.53 and an EV to EBITDA of 11.81, Amgen's valuation metrics reflect a more attractive investment opportunity. Additionally, Amgen's return over the past year shows a decline of 7.01%, contrasting with the S&P 500's gain of 14.08%, which highlights the potential for recovery given its current valuation. Overall, Amgen's strong ROE of 116.13% and solid dividend yield of 3.18% further support the case for its undervaluation.

Is Amgen, Inc. technically bullish or bearish?

As of October 24, 2025, Amgen, Inc. shows a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 year-to-date and over the past year, suggesting caution in the current market environment.

As of 24 October 2025, the technical trend for Amgen, Inc. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The MACD shows a conflicting mildly bullish signal on the weekly chart but is mildly bearish on the monthly chart. The Dow Theory indicates a mildly bullish stance on the weekly timeframe but is also mildly bearish monthly. <BR><BR>In terms of performance, Amgen's returns have lagged behind the S&P 500 across multiple periods, with a year-to-date return of 11.94% compared to the S&P 500's 15.47%, and a one-year return of -7.58% versus the S&P 500's 16.90%. Overall, the mixed signals suggest caution in the current market environment.